vaxneuvance
merck sharp & dohme b.v. - pneumococcal polysaccharide conjugate vaccine (adsorbed) - pneumococcal infekcije - pneumococcus, purified polysaccharides antigen conjugated - vaxneuvance is indicated for active immunisation for the prevention of invasive disease, pneumonia and acute otitis media caused by streptococcus pneumoniae in infants, children and adolescents from 6 weeks to less than 18 years of age. vaxneuvance is indicated for active immunisation for the prevention of invasive disease and pneumonia caused by streptococcus pneumoniae in individuals 18 years of age and older. pogledajte odjeljke 4. 4 i 5. 1 za informacije o zaštiti od specifičnih pneumokoknih serotipova. the use of vaxneuvance should be in accordance with official recommendations.
lysakare
advanced accelerator applications - l-arginine hydrochloride, l-lysine hydrochloride - Лучевые oštećenja - detoxifying agents for antineoplastic treatment - lysakare indiciran za smanjenje izloženosti zračenju kada bubrega peptid-рецепторного радионуклидной terapije (prrt) s Лютеций (177lu) oxodotreotide kod odraslih.
cuprymina
a.c.o.m. - advanced center oncology - bakar (64cu) klorid - radionuklidno slikanje - various diagnostic radiopharmaceuticals - cuprymina je radioaktivni farmaceutski prekursor. nije namijenjen izravnoj uporabi u bolesnika. ovaj medicinski proizvod mora se koristiti samo za radioaktivno obilježavanje molekula nosača, koji su posebno razvijeni i odobreni za radioaktivno obilježavanje s ovim radionuklidom.
elegance kit
medicina-promet d.o.o., zagreb - mjerač za praćenje razine glukoze u krvi
vaxneuvance 2 µg/0.5 ml+ 2 µg/0.5 ml+ 2 µg/0.5 ml+ 2 µg/0.5 ml+ 2 µg/0.5 ml+ 4 µg/0.5 ml+ 2 µg/0.5 ml+ 2 µg/0.5 ml+ 2 µg/0.5 ml+
merck sharp & dohme bh d.o.o. - pneumokokus, prečišćeni polisaharidni antigen konjugovani - suspenzija za injekciju u napunjenom špricu - 2 µg/0.5 ml+ 2 µg/0.5 ml+ 2 µg/0.5 ml+ 2 µg/0.5 ml+ 2 µg/0.5 ml+ 4 µg/0.5 ml+ 2 µg/0.5 ml+ 2 µg/0.5 ml+ 2 µg/0.5 ml+ 2 µg/0.5 ml - jedna doza (0,5 ml) sadrži 2 µg pneumokoknog polisaharida serotipova 1, 3, 4, 5, 6a, 7f, 9v, 14, 18c, 19a, 19f, 22f, 23f i 33f i 4 µg serotipa 6b, konjugovanih na proteinski nosač crm197
vaxneuvance 2 µg/0.5 ml+ 2 µg/0.5 ml+ 2 µg/0.5 ml+ 2 µg/0.5 ml+ 2 µg/0.5 ml+ 4 µg/0.5 ml+ 2 µg/0.5 ml+ 2 µg/0.5 ml+ 2 µg/0.5 ml+
merck sharp & dohme bh d.o.o. - pneumokokus, prečišćeni polisaharidni antigen konjugovani - suspenzija za injekciju u napunjenoj šprici - 2 µg/0.5 ml+ 2 µg/0.5 ml+ 2 µg/0.5 ml+ 2 µg/0.5 ml+ 2 µg/0.5 ml+ 4 µg/0.5 ml+ 2 µg/0.5 ml+ 2 µg/0.5 ml+ 2 µg/0.5 ml+ 2 µg/0.5 ml - jedna doza (0,5 ml) sadrži 2 µg pneumokoknog polisaharida serotipova 1, 3, 4, 5, 6a, 7f, 9v, 14, 18c, 19a, 19f, 22f, 23f i 33f i 4 µg serotipa 6b, konjugovanih na proteinski nosač crm197
advance mail sling sistem ams sustavi za operativno lijeČenje stresne ili statiČke urinarne inkontinencije kod muškaraca
rud-kom d.o.o., zagreb - sustavi za operativno liječenje stresne ili statičke urinarne inkontinencije kod muškaraca
advanced perfuzion sistem 1 (system 1), sarns tcm ii (tcm ii) i cdi 500/101 sistem (cdi 500/101)
medicem servis d.o.o., zagreb - sistem za ekstrakorporalnu (izvantjelesnu) cirkulaciju
aldactone 25 mg obložene tablete
esteve pharmaceuticals gmbh, hohenzollerndamm 150-151, berlin, njemačka - spironolakton - obložena tableta - 25 mg - urbroj: 1 tableta sadrži 25 mg spironolaktona
firmagon
ferring pharmaceuticals a/s - degarelix - prostatske neoplazme - endokrinska terapija - firmagon is a gonadotrophin releasing hormone (gnrh) antagonist indicated:- for treatment of adult male patients with advanced hormone-dependent prostate cancer. - for treatment of high-risk localised and locally advanced hormone dependent prostate cancer in combination with radiotherapy. - as neo-adjuvant treatment prior to radiotherapy in patients with high-risk localised or locally advanced hormone dependent prostate cancer.